Saratov JOURNAL of Medical and Scientific Research

Evaluation of the development time and characteristics of the clinical manifestations of chronic prostatitis/chronic pelvic pain syndrome in men, taking into account the age and body weight according to UPOINT classification

Year: 2020, volume 16 Issue: №1 Pages: 69-72
Heading: Urology Article type: Original article
Authors: Popkov V.M., Loyko V.S., Mikhaylov I.V.
Organization: Kuban State Medical University, Saratov State Medical University

Objective: to study the terms and clinical features of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) development using UPOINT classification in men from 32 to 60 age depending on body weight. Material and Methods. A total of 121 men with CP/CPPS with various body weight aged by 32-60 years were observed. Body Mass Index (BMI) was used to prove absence or presence of overweight and obesity. The diagnosis of CP/CPPS in patients was based on the information of anamnesis, analysis of health cards and case histories. Differential diagnosis of CP/CPPS forms was organized by the cytological and bacteriological studies of prostatic secretion. Results. Only 26.4% of patients with CP/CPPS showed normal body weight. It was observed that in men with excess body weight and obesity the CP/CPPS developed at more earlier periods of their life. The differences of phenotype and clinical manifestations in patients with obesity and normal body index were determined according to the UPOINT classification. Conclusion. The risk of chronic pelvic pain syndrome development in men with obesity (BMI>30) under the 45 years increases in 2.3 times compared to men with normal body weight. The results of men phenotyping with chronic pelvic pain syndrome and obesity snowed the prevalence for P, О and N domains from UPOINT classification thus represent the predominance of disuric symptoms with expressed psychogenic features on the background of pain feelings outside the pelvis.

1. Vinarov AZ. Modern view on etiology, pathogenesis and treatment of chronic pelvic pain syndrome. Urology 2017; (1): 114-22.
2. Popkov VM, Chekhonatskaya ML, Loyko VS, et al. Hemodynamic disturbances in patients with benign prostatic hyperplasia and accompanied by chronic prostatitis. Bulletin of the Volgograd State Medical University 2015; 55 (3): 129-132.
3. Engeler D, et al. EAU Guidelines on Chronic Pelvic Pain. 2014; 132 p.
4. Zajcev AV, Sharov MN, Pushkar' DYu, et al. Chronic pelvic pain: Metodical recommendations. Moscow, 2016; 45 p.
5. Fibbi В, Penna G, Fibbi В, Morelli A. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010;33:475-88.
6. Attia TJ, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network metaanalysis. JAMA 2011; 305 (1): 78-86.
7. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic Syndrome and Urological Diseases. Rev Urol 2010; 2 (4): 157-80.
8. Grabe M, Bartoletti R, Bjerklund Johansen ТЕ, et al. Guidelines on urological infections. European Association of Urology, 2015; p. 42-6.
9. Cornu JN, et al. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 2010; 58 (3): 450-6.
10. Tyuzikov IA, Ivanov AP Abacterial syndrome of chronic pelvic pain in men as a multidisciplinary problem. Fundamental study 2012; (1): 121-24.
11. Gorbachinsky I, et al. Metabolic syndrome and urological diseases. Rev Urol 2010; 12 (4): 157-80.
12. Polackwich AS, Shoskes DA. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate cancer prostatic dis 2016; 19 (2): 132-8.
13. Shoskes DA, Nickel JC. Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 2010; 75 (6): 1249-53.
14. Samplaski MK, Li J, Shoskes DA. Clustering of UPOINT domains and subdomains in men with chronic prostatitis/chronic pelvic pain syndrome and contribution to symptom severity. J Urol 2012; 188(5): 1788-93.
15. DolgovAB, Popkov VM, ChurakovAA. Chronic abacterial prostatitis/chronic pelvic pain syndrome: a modern view on pathogenesis. Modern Problems of Science and Education 2016; (4): 62.
16. Treatment method of prostate adenoma combined with chronic abacterial prostatitis: Patent RUS 2568369; 10.27.2014/Popkov VM, Kirichuk VF, Loyko VS [et al.].
17. Popkov VM, Kirichuk VF, Loyko VS, et al. Experience of terahertz therapy in benign prostatic hyperplasia combined with chronic abacterial prostatitis. Saratov Journal of Medical Scientific Research 2014; 10 (4): 649-54.
18. Tyuzikov IA. Chronic prostatitis/chronic pelvic pain syndrome metabolic syndrome in men: pathophysiological correlation and prospects of pathogenetic multimodal therapy. Medical alphabet 2014; 6: 26-31.
19. Lutov YuV, Vasilyeva OV, Novikova EG, Selyatitskaya VG. Correlation of metabolic syndrome and its components with insulin resistance and visceral fat dysfunction in men. Modern problems of science and education 2017; 3: 48.
20. Novikova EG, Mitrofanov IM, Lutov YuV, Selyatitskaya VG. Metabolic syndrome and its association with chronic prostatitis and erectile dysfunction in men of mature age. Health. Medical ecology. Science 2011; 1 (44): 69-70.
21. Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73 (5): 602-12.
22. Smith CP Male chronic pelvic pain: An update. Indian J Urol 2016; 32(1): 34-9.

2020_01_069-072.pdf294.04 KB

No votes yet